Zhong Guo Jing Ji Wang·2026-01-09 07:24Core Viewpoint - The company, Puni Testing, has announced a projected net loss for the year 2025, indicating an improvement compared to the previous year's losses [1][5]. Financial Performance - The projected net loss for 2025 is estimated to be between 200 million yuan and 250 million yuan, compared to a loss of 356.31 million yuan in the previous year, reflecting a decrease in losses by approximately 43.87% [1][2]. - The net profit after excluding non-recurring gains and losses is expected to be a loss of 211 million yuan to 261 million yuan, compared to a loss of 380.09 million yuan in the previous year, indicating a reduction in losses by about 44.49% [1][2]. Historical Context - Puni Testing was listed on the Shenzhen Stock Exchange's ChiNext board on September 16, 2020, with an initial issuance of 19 million shares at a price of 44.47 yuan per share [2]. - The total amount raised from the initial public offering (IPO) was 845 million yuan, with a net amount of 769 million yuan after deducting issuance costs [3]. Fund Utilization - The funds raised from the IPO were intended for various projects, including the construction of production facilities, a research and testing base, and a biopharmaceutical diagnostic reagent research center [3]. Recent Financial Results - In 2024, the company reported an operating revenue of 1.541 billion yuan, a decrease of 37.54% year-on-year [5]. - The net profit attributable to shareholders was a loss of 356 million yuan, a significant decline of 430.58% compared to the previous year [5]. - The net cash flow from operating activities was 36.02 million yuan, down 89.02% year-on-year [5].